Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1141 to 1155 of 1766 results for patient safety

  1. Low back pain and sciatica in over 16s: assessment and management (NG59)

    This guideline covers assessing and managing low back pain and sciatica in people aged 16 and over. It outlines physical, psychological, pharmacological and surgical treatments to help people manage their low back pain and sciatica in their daily life. The guideline aims to improve people’s quality of life by promoting the most effective forms of care for low back pain and sciatica.

    NICE guideline
    Last updated
    11 December 2020
    View recommendations

    Sections for NG59

  2. Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (TA275)

    Evidence-based recommendations on apixaban (Eliquis) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.

    Technology appraisal guidance
    Last updated
    2 July 2021
    View recommendations

    Sections for TA275

  3. Difelikefalin for treating pruritus in people having haemodialysis (TA890)

    Evidence-based recommendations on difelikefalin (Kapruvia) for pruritus in adults with chronic kidney disease having haemodialysis.

    Technology appraisal guidance
    Published
    17 May 2023
    View recommendations

    Sections for TA890

  4. The evidence for treating an acute migraine attack is adequate but, for treating subsequent attacks, is limited in quality and quantity. So, for treating acute migraine, this procedure should only be used with special arrangements for clinical governance, consent, and audit or research. Find out what special arrangements mean on the NICE interventional procedures guidance page . The evidence for preventing migraine is inadequate in quality. So, for preventing migraine, this procedure should only be used in the context of research. Find out what only in research means on the NICE interventional procedures guidance page.

    Ensure that people and their families and carers understand the procedure's safety and efficacy, and any uncertainties about these....

    Research recommendation
    Published
    7 November 2022

  5. Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (TA426)

    Evidence-based recommendations on dasatinib (Sprycel), nilotinib (Tasigna) and imatinib (Glivec) for untreated chronic myeloid leukaemia in adults.

    Technology appraisal guidance
    Published
    21 December 2016
    View recommendations

    Sections for TA426

  6. The SpyGlass direct visualisation system for diagnostic and therapeutic procedures during endoscopy of the biliary system (MIB21)

    NICE has developed a Medtech Innovation Briefing (MIB) on the SpyGlass direct visualisation system for diagnostic and therapeutic procedures during endoscopy of

    Medtech innovation briefing
    Published
    12 February 2015

  7. Mini/micro screw implantation for orthodontic anchorage (IPG238)

    Evidence-based recommendations on mini/micro screw implantation for orthodontic anchorage. This involves inserting small screws into the jaw bone to create anchors that support tooth realignment.

    Interventional procedures guidance
    Published
    28 November 2007
    View recommendations

    Sections for IPG238

  8. Optowire for measuring fractional flow reserve (MIB199)

    NICE has developed a medtech innovation briefing (MIB) on Optowire for measuring fractional flow reserve .

    Medtech innovation briefing
    Published
    3 December 2019

  9. Tocilizumab for the treatment of rheumatoid arthritis (TA247)

    Evidence-based recommendations on tocilizumab (RoActemra) for treating rheumatoid arthritis in adults.

    Technology appraisal guidance
    Published
    22 February 2012
    View recommendations

    Sections for TA247

  10. Spiral Flow peripheral vascular graft for treating peripheral arterial disease (MIB34)

    NICE has developed a medtech innovation briefing (MIB) on the Spiral Flow peripheral vascular graft for treating peripheral arterial disease

    Medtech innovation briefing
    Published
    21 July 2015

  11. Optilume for anterior urethral strictures (MIB241)

    NICE has developed a medtech innovation briefing (MIB) on Optilume for anterior urethral strictures .

    Medtech innovation briefing
    Published
    5 January 2021

  12. Current evidence on the safety and efficacy of radially emitting laser fibre treatment of an anal fistula is limited in quantity and quality. Therefore, although there are no major safety concerns, this procedure should only be used with special arrangements  for clinical governance, consent, and audit or research.

    Recommendation ID IPG644/1 Question Current evidence on the safety and efficacy of radially emitting laser fibre treatment of an anal...

    Research recommendation
    Published
    15 November 2019

  13. NICE encourages further research on corticosteroid-eluting bioabsorbable stent or spacer insertion during endoscopic sinus surgery and, specifically, controlled studies designed for between-patient (rather than within-patient) comparisons. Outcomes should include symptom scores, quality of life and the need for retreatment in the long term. All complications should be reported. NICE may update this guidance on publication of further evidence.

    and, specifically, controlled studies designed for between-patient (rather than within-patient) comparisons. Outcomes...

    Research recommendation
    Published
    6 April 2016

  14. Minimally invasive sacroiliac joint fusion surgery for chronic sacroiliac pain (IPG578)

    Evidence-based recommendations on minimally invasive sacroiliac joint fusion surgery for chronic sacroiliac pain in adults. This involves fixing the sacrum to the ilium using 2 or 3 metal implants.

    Interventional procedures guidance
    Published
    5 April 2017
    View recommendations

    Sections for IPG578

  15. Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer (TA801)

    Evidence-based recommendations on pembrolizumab (Keytruda) with paclitaxel or nab-paclitaxel for triple-negative, locally recurrent unresectable or metastatic breast cancer in adults who have not had chemotherapy for metastatic disease.

    Technology appraisal guidance
    Published
    29 June 2022
    View recommendations

    Sections for TA801